Answers are grounded in this paper and cite their sources.
Infiltrative lung disease is a well-known complication of antineoplastic agents in patients with hematological malignancies. Novel agents are constantly being added to available treatments. The present review discusses different pulmonary syndromes, pathogenesis and management of these novel agents. La maladie pulmonaire infiltrante est une complication bien connue des antinéoplasiques chez les patients atteints de tumeurs hématologiques malignes. De nouveaux agents s’ajoutent constamment aux traitements disponibles. La présente analyse porte sur divers syndromes pulmonaires, différentes pathogenèses et diverses prises en charge de ces nouveaux agents.
No takes yet. Share an insight, caveat, or question.
Vahid et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: